Patent 11,357,782 (US) Treprostinil dry powder inhaler “single-event dose” pulmonary hypertension: scope, claim map, and US patent landscape
United States Patent US 11,357,782 claims a tightly specified pulmonary hypertension treatment method using a treprostinil dry powder inhaler (DPI) that delivers a single event dose of 15 to 90 micrograms of treprostinil (or a pharmaceutically acceptable salt) in 1 to 3 breaths, completed in <5 minutes, with ≥5 micrograms per breath and coordinated actuation (one actuation per breath). Claim scope expands through dose-multiple administration (≥3 hours later), optional particle and excipient constraints (e.g., <5 µm particles; no metacresol), and defined pharmacokinetic targets (Cmax-related metrics and timing). The overall landscape is driven by three overlapping IP pillars: (i) treprostinil powder formulations and excipient/extratherm parameters, (ii) DPI device dosing control and actuation-to-inhalation coordination, and (iii) clinical regimens and exposure targets for pulmonary arterial hypertension (PAH) and related pulmonary hypertension phenotypes.
What exactly does US 11,357,782 claim for treprostinil inhaled powder pulmonary hypertension (scope summary)?
Core independent claim (Claim 1) scope in one line:
A pulmonary hypertension treatment method using a treprostinil DPI delivering a 15–90 µg single event dose in 1–3 breaths, ≥5 µg per breath, administered by coordinated actuation (one actuation per breath), completed in <5 minutes, with additional single event dose ≥3 hours later.
Claim 1 essential limitations (each is material for infringement)
- Condition/indication: “method of treating pulmonary hypertension in a human suffering from pulmonary hypertension.”
- Active form: powder formulation of treprostinil or pharmaceutically acceptable salt.
- Delivery modality: dry powder inhaler (DPI).
- Single event dose size: 15 to 90 micrograms treprostinil/salt.
- Breath count: delivered in 1 to 3 breaths.
- Per-breath minimum: ≥5 micrograms inhaled per breath.
- Administration time window: entire single event dose in <5 minutes.
- Coordination requirement: DPI is configured to administer the entire single event dose in <5 minutes with inhaled microgram dose per breath via coordinated actuation with each breath (one actuation per breath).
- Repeat dosing interval: “administration of an additional single event dose … occurs at least 3 hours later.”
- User-controlled regimen: patient administers entire dose within <5 minutes by inhalation and coordination (one actuation per breath).
Dependent claim expansion (Claims 2–11)
- Claim 2: repeats the ≥3 hours-later additional single event dose limitation in explicit dependent form.
- Claim 3: dose may be repeated “several times per day” (broad rhythm flexibility so long as Claim 1’s minimum interval is met).
- Claim 4: powder particles <5 µm.
- Claim 5: powder formulation contains no metacresol.
- Claim 6: single event dose inhaled in < about 1 minute.
- Claim 7: alternative expression of per-breath dose: DPI configured for ≥15 µg per breath, and human inhales ≥15 µg per breath by coordinated actuation.
- Claim 8: pharmacokinetic exposure: maximal treprostinil plasma concentration ≥0.65 ± 0.28 ng/mL (Cmax threshold with stated variability).
- Claim 9: Tmax about 10–15 minutes after inhalation.
- Claim 10: recites dose range 15–90 µg (belt-and-suspenders dependent).
- Claim 11: breath interval about 6 seconds (tightens timing mechanics).
Practical infringement posture
US 11,357,782 is not just “treprostinil by inhalation.” It is a method-of-treatment claim requiring a defined dose architecture (microgram dose partitioned across 1–3 breaths), a defined timing discipline (<5 minutes total), and a defined actuation-to-breath coordination. It also contains a meaningful formulation excipient hook (no metacresol) and powder particle size hook (<5 µm), plus exposure markers (Cmax and Tmax). Any design-around must break at least one of those pillars.
How broad are the claims across treprostinil salts, particle sizes, excipients, and dosing schedules?
Breadth is concentrated in the dose range and repetition window; narrowness is concentrated in delivery mechanics and excipient/particle constraints.
Treprostinil chemical scope
- Covers treprostinil and “pharmaceutically acceptable salt thereof.” This typically supports a salt-based workaround only if a defendant can argue the salt is not “pharmaceutically acceptable” in the claimed context or does not meet other limitations (dose, delivered microgram per breath, actuation coordination, timing, PK).
Dose range breadth (15–90 µg)
- Claim 1 allows any single event dose within 15–90 µg.
- Claim 7 tightens to ≥15 µg per breath, which can be a larger constraint depending on the defendant’s “per-breath partitioning.”
Breath count breadth (1–3 breaths)
- Delivery must be in 1 to 3 breaths. A regimen that forces 4+ breaths to deliver the same microgram total would avoid this claim if it can show no equivalent “single event dose delivered in 1 to 3 breaths.”
Time completion breadth (<5 minutes)
- Claim 1 requires <5 minutes total. A defendant device/regimen that makes the full dose take ≥5 minutes does not meet this limitation.
Coordination/actuation mechanics (one actuation per breath)
- This is one of the most enforceable elements because it ties method performance to device control. If a competitor uses a different control approach where actuation is not coordinated 1:1 with each separate inhalation, it may defeat the “coordinated actuation … one actuation … for each separate breath” language.
Excipient limitation (no metacresol)
- Claim 5 explicitly requires “no metacresol.” This is a clean dependent claim that reduces coverage if a product uses metacresol in the powder blend.
- However, the independent Claim 1 does not require absence of metacresol. So metacresol-containing products can still infringe Claim 1 if they meet the core dose delivery mechanics and timing.
Particle size limitation (<5 µm)
- Claim 4 limits particle size to <5 µm (dependent). A competitor can seek avoidance by using a powder with a meaningful fraction ≥5 µm, but only avoids Claim 4, not necessarily Claim 1.
PK limitation hook (Cmax and Tmax)
- Claim 8 and Claim 9 create measurable biological performance targets. In litigation, this can become a battleground of:
- assay method,
- study design,
- comparator dosing architecture,
- and whether the defendant’s regimen “provides” the required maxima and timing.
Even if a defendant matches the physical dose delivery architecture, it could attempt to shift pharmacokinetic profile outside the claimed PK metrics. Conversely, plaintiffs will rely on product-in-use data.
What patents likely surround US 11,357,782: formulation, device, and dosing regimen clusters?
Because only the claims text for US 11,357,782 is provided, the landscape below is structured as an IP map of claim-adjacent patent families that typically co-occur for inhaled treprostinil DPI products in the US. This is the practical lens for freedom-to-operate and design-around analysis.
Cluster A: Treprostinil dry powder formulation (powder chemistry and particle engineering)
Typical claim themes:
- treprostinil vs salt form used in DPI powder,
- excipient systems (e.g., mannitol, leucine, sugars, buffering systems),
- particle size distributions (including <5 µm),
- stability and aerosolization performance (fine particle fraction, flowability),
- metacresol presence or absence (directly implicated by Claim 5).
Why it matters for US 11,357,782:
Claim 1 is a method claim with a powder formulation prerequisite; formulation patents can overlap even when device dosing is the same.
Cluster B: DPI device mechanics and dose metering architecture
Typical claim themes:
- single dose cartridge or reservoir,
- dose metering to deliver a “single event dose,”
- breath-sensing and actuation coordination,
- ensuring delivery in 1–3 breaths,
- “entire dose in <5 minutes” achieved by device configuration,
- actuators configured for one actuation per breath.
Why it matters for US 11,357,782:
Claim 1 reads on a DPI “configured” to administer the entire single event dose under these performance conditions. Device design directly drives infringement exposure.
Cluster C: Dosing regimen and pharmacokinetic targets
Typical claim themes:
- dosing interval (≥3 hours later; “several times per day”),
- dosing per breath and number of inhalations,
- PK targets like Cmax and Tmax ranges (Claim 8–9),
- methods of treatment of pulmonary hypertension/PAH with inhaled treprostinil.
Why it matters for US 11,357,782:
Even if device/formulation are similar, regimen claims can determine infringement and validity leverage in Hatch-Waxman style disputes.
Cluster D: Composition-of-matter vs method overlap
If US 11,357,782 is a method claim, it still sits in a bigger ecosystem where:
- composition-of-matter patents may block generic entry until expiration,
- method/regimen patents can block “use” even if a generic substitutes device and/or excipients, depending on how the generic administers dose.
Which claim elements are most likely to drive litigation outcomes for US 11,357,782?
Most likely “hard to avoid” elements
- Dose architecture: 15–90 µg delivered as a “single event dose” in 1–3 breaths.
- Per-breath minimum: ≥5 µg inhaled per breath.
- Timing: <5 minutes total for the single event dose.
- Coordination: coordinated actuation with each breath, one actuation per breath.
- Repeat interval: additional single event dose at least 3 hours later.
Likely “fact-intensive” elements
- PK targets: Cmax threshold and Tmax timing windows.
- Particle size: <5 µm (dependent) if asserted.
- Metacresol absence: depends on formulation.
Likely “availability of evidence” issues
- PK claims require human data from dosing studies.
- “Configured to” device language invites evidence from engineering specs and user trials demonstrating performance.
How does US 11,357,782 compare to typical treprostinil inhalation IP in the US?
US 11,357,782 is differentiated by its “single event dose in 1–3 breaths with coordinated actuation and <5 minutes” mechanics.
Many treprostinil DPI patents focus on:
- the DPI itself,
- the powder composition,
- or general inhaled dosing without such strict breath-by-breath actuation/time completion constraints.
Here, Claim 1 is structured to capture the operational regimen and device control logic. That makes it closer to a system-level claim than a pure formulation claim.
What generic entry risks exist if a company markets inhaled treprostinil DPI with different devices or dosing mechanics?
A generic or follow-on treprostinil DPI company attempting to enter while US 11,357,782 is live would face two main risk paths:
Risk path 1: “Same outcome, different mechanism” still matches claim architecture
If a competitor delivers treprostinil in 1–3 breaths, with ≥5 µg per breath and <5 minutes completion, and uses coordinated one-actuation-per-breath control, they risk direct infringement of Claim 1.
Risk path 2: “Different formulation” does not avoid method claim requirements
Even if a competitor adds metacresol or uses different particle sizes:
- It may avoid dependent Claim 5 or Claim 4,
- but it can still infringe independent Claim 1 if the delivery mechanics and dosing regimen align.
PK risk
Even if physical dosing is matched but PK shifts:
- Claim 8 and Claim 9 can still create infringement exposure if the competitor’s dosing nevertheless yields the required Cmax and Tmax metrics.
Key takeaways for business decisions
- US 11,357,782 claim scope is performance-driven: it targets a treprostinil DPI method with a defined single-event dose (15–90 µg), breath partition (1–3 breaths; ≥5 µg/breath), completion time (<5 minutes), and actuation-to-breath coordination (one actuation per breath), plus a minimum interval for subsequent dosing (≥3 hours).
- Design-around options are specific. Avoidance must break at least one hard limitation: breath count, per-breath microgram delivery, total administration time, coordinated actuation mapping, or dosing interval.
- Formulation-only changes are insufficient to avoid the independent claim. Metacresol absence and particle size (<5 µm) are dependent hooks, not independent requirements.
- Device mechanics and patient use protocol are central to infringement risk because Claim 1 is framed around a DPI “configured” to deliver dose in a constrained time with coordinated actuation.
- PK claim elements can become secondary battlegrounds: even with physical dose parity, PK evidence may determine exposure under Claims 8 and 9.
FAQs
1) Does US 11,357,782 require metacresol-free powder to infringe?
No. Metacresol absence appears in dependent Claim 5. Independent Claim 1 does not require “no metacresol.”
2) How can a competitor avoid the “1 to 3 breaths” limitation?
By designing a regimen where the single event dose is delivered using 4 or more breaths, so it no longer fits “delivered in 1 to 3 breaths.”
3) Is “less than 5 minutes” measured from start to finish of the single event dose?
The claim requires the entire single event dose be administered in less than 5 minutes with coordinated actuation aligned to each breath.
4) What is the role of the pharmacokinetic limits in this patent?
They are separate dependent claim elements (Claims 8 and 9). They can be asserted only if the accused method also satisfies all independent and those dependent elements.
5) Can a product with different particles still infringe?
Yes. Particle size <5 µm is only in dependent Claim 4. A product can still infringe independent Claim 1 if other delivery mechanics match.
References
- US Patent Application/Publication: US 11,357,782. (Claims provided in prompt).
